Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11350855.
- Also identified by PMC identifier 1753660.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To test lower dose immunoglobulins as a maintenance treatment in a patient with refractory polymyositis. In a patient with longstanding refractory polymyositis, intravenous (IV) immunoglobulin treatment was introduced at a standard dose (2 g/kg monthly). After a few treatment courses, doses were reduced to 0.8 g/kg monthly, allowing perfusion over one single day. Although response to the standard dose was only partial, reduction of subsequent doses did not alter the evolution. On the contrary, the evolution was marked by further improvement, which has been sustained over the following year. Lower dose IV immunoglobulins as a maintenance treatment were used with excellent results in a case of refractory polymyositis allowing considerable reduction in treatment costs. Further trials should be undertaken to evaluate this interesting alternative.
Medical subject headings
- Immunoglobulins, Intravenous
- Polymyositis